Fail Early, Fail Fast

“Biotech executives are addressing a multitude of strategic priorities daily. However, prioritizing indications and executing the right portfolio program are becoming more challenging. If you are going to fail eventually, it’s better, and much less costly, to fail earlier, so fail fast.”